

Adult Immunization Board (AIB) *Technical meeting:*

Advancing vaccination strategies for the older adults: insights into epidemiology, immunity, and implementation

7-8 May 2025 Warsaw, Poland

PRELIMINARY MEETING AGENDA





Meeting Objectives

- Clarify the definition of older adults in the context of vaccination by considering factors such as chronological age, comorbidities, and biological markers like immunosenescence and frailty.
- Review and discuss vaccines and vaccination programs targeting older adults across Europe.
- Address the unique challenges and opportunities in conducting vaccination studies, and especially clinical trials, with older adults.
- Explore the mechanisms and factors affecting the efficacy, effectiveness, safety and durability (including boosters) of vaccine responses in older adults and discuss strategies (like adjuvants and higher doses) to enhance immune responses. Discuss specific characteristics of different vaccines for older adults.
- Discuss implementation of vaccination in older adults at the policymakers, organizational and population levels. Identify strategies, including best practices and successes, to increase vaccination coverage in both community and other care settings, and address communication and logistical challenges to ensure program sustainability and equity.

Intended Impact and Target Audience

The population in Europe is ageing rapidly, with the proportion of older adults increasing significantly. As a result, the need to protect this demographic group through tailored vaccination efforts has become more urgent within lifelong immunization programs across Europe. This meeting seeks to provide essential insights and strategies to improve vaccine effectiveness, immunity durability, and uptake among older adults. By gathering experts in immunology, vaccine development, geriatrics and public health, the meeting will address the unique challenges faced by older adults, such as frailty, comorbidities, and immunosenescence. The discussions will support National Immunization Programs by sharing the latest information and best practices to boost vaccination coverage, customize strategies, and ensure sustained protection against vaccine-preventable diseases for this growing segment of the population.

More information about the adult immunization board:

www.adultimmunizationboard.org // AIB introduction video

Meeting Venue

Hotel Polonia, Aleje Jerozolimskie 45, 00-692 Warszawa, Poland

Preliminary agenda

[TBD – To Be Decided, TBC – To Be Confirmed]

DAY 1 – MAY 7TH, 2025

Session 1: Opening, introduction and objectives Chairs: TBD				
9.05	Introduction of Adult Immunization Board	Pierre Van Damme (Centre for Evaluation of Vaccination, University of Antwerp, Belgium) Paolo Bonanni (Department of Health Sciences, University of Florence, Italy)		
9.15	Overview of the objectives of the meeting + Why focusing on older adults	Stefania Maggi (European Interdisciplinary Council on Ageing)		
9.30	Tour de table			
Session 2: Setting the scene: health prevention and vaccination strategies of older adults in Europe Chairs: TBD				
10.00	Enhancing health in an ageing population: WHO EURO's datadriven approach to prevention strategies (including vaccination) for older adults	Yongjie Yon (Online) (WHO EURO)		
10.25	Clarifying the older adults population for vaccination strategies: exploring age, comorbidities, immunosenescence, frailty as factors	Claudio Franceschi (Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy)		
10.50	Discussion			
11.10	Coffee Break			
11.40	Overview on current vaccines, recommendations and national vaccination plans in the older adults in Europe	AIB/IFA secretariat (TBC)		
12.00	Geriatric/GP perspectives from three different EU countries on their countries respective vaccination recommendations and strategic plans for older adults (barriers/opportunities for the future)			

	 Felipe Froes (Hospital Pulido Valente, Centro Hospitalar Universitário Lisboa Norte, Lisbon, Portugal) Poland (TBD) Denmark (TBD) 				
12.20	Discussion				
12.40	Lunch				
Session 3: From clinical trials to real-world data: challenges and opportunities in the					
conduction of trials					
Chairs: TBD					
13.30	Overview of the difficulties and opportunities of vaccine trials (e.g. pragmatic trials) targeting frail and older adults.	T.Biering-Sorensen (University of Copenhagen, Department of Biomedical Sciences, Denmark)			
13.50	Use of Real-World Data to complement experimental studies	Domnich Alexandr (Hygiene Unit, San Martino Policlinico Hospital - IRCCS for Oncology and Neurosciences, Genoa, Italy)			
14.10	Discussion				
Session 4: Understanding specific characteristics of different vaccines for older adults					
Chairs: TBD	Chairs: TBD				
14.30	4.1 Immunological mechanisms of vaccine-induced immune response in the older adults	Birgit Weinberger (Institute for Biomedical Aging Research, University of Innsbruck, Austria)			
14.45	4.2 The effects of comorbidity on the vaccination response in older adults	Debbie van Baarle (Center for Infectious Disease Prevention, National Institute for Public Health and the Environment, Bilthoven, the Netherlands; Center for Translational Immunology, University Medical Center Utrecht, University of Utrecht, Utrecht, the Netherlands)			
15.00	Discussion				
15.15	Coffee Break				
	4.3 Specific characteristics of different vaccines for older adults (Part 1) Each talk will start with 2 general slides, indicating what vaccines are currently available and some general characteristics, followed by a more detailed explanation of a specific characteristic of the vaccine				
15.45	Herpes Zoster: Specific topic: duration in older adults	J. Diez Domingo (TBC)			
16.00	Pneumococcal disease: Specific topic: future vaccines	Antoni Torres (Unidad de Cuidados Intensivos Respiratorios, Departamento de Neumología y Alergia Respiratoria, Hospital Clínic, Universitat de Barcelona, IDIBAPS (Institut d'Investigacions August Pi i Sunyer),			

		CIBERES (Ciber de Enfermedades Respiratorias), Barcelona, Spain)		
16.15	Tdap: Specific topic: boosters in older adults and differences between countries	Tino F Schwarz (Central Laboratory and Vaccination Centre, Stiftung Juliusspital, Würzburg, Germany)		
16.30	RSV: Specific topic: Need for revaccination? When and how to organize it?	Élisabeth Botelho-Nevers (Groupe Immunité des Muqueuses et Agents Pathogènes, COMUE of Lyon, Saint-Etienne, France; Infectious Diseases Department, University Hospital of Saint-Etienne, France)		
16.45	Discussion			
17.15	Closure of day 1			
	DAY2 – MAY8	TH, 2025		
4.3 Specific characteristics of different vaccines for older adults (Part 2)				
9.00	Influenza: Specific topic: High-dose and adjuvanted vaccines	Colin Russel (TBC)		
9.15	COVID-19/SARS-CoV-2: Specific topic: Different platforms (e.g. mRNA)	Merryn Voysey (TBC)		
9.30	Discussion			
	Session 5: Implementing vaccir on multiple I			
Chairs: TBD	on manple i	64613		
9.45	The policymakers level: Vaccine impact assessment and economic value of vaccination in aging adults	Lotte Steuten (Office of Health Economics, UK)		
10.10	The organizational level: what are challenges in reaching older adults and opportunities (e.g. coadministration)	Sofia Duque (Hospital São Francisco Xavier, Internal Medicine Department, Orthogeriatric Unit, Portugal)		
10.35	Discussion			
10.45	Coffee break			
11.15	The population level: communicating the importance of vaccination for healthy aging	Cornelia Betsch (TBC)		
11.40	Discussion			
Session 6: Breakout Groups and meeting closing				
Chairs: TBD				
12.00	Breakout Groups (potential topics are decided during the course of the meeting)			
13.00	Plenary feedback			

13.30	Lunch			
Chairs: TBD				
14.30	Meeting summary by AIB rapporteur	Katherine Newell		
15.00	Closing remarks and Closing of the Meeting			